Mesothelioma Legal News

The Missouri Court of Appeals upheld a landmark jury verdict that said long-term use of Johnson & Johnson’s talc products, possibly contaminated with asbestos fibers, had caused ovarian cancer in 22 women. The Court of Appeals also reduced the earlier, record-setting award for punitive and compensatory damages from $4.69 billion to $2.1 billion. A Johnson…

The post Johnson & Johnson Talc-Asbestos Verdict Upheld, Award Cut appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Five different research groups at the American Society of Clinical Oncology annual meeting last month made presentations on the effectiveness of tazemetostat, a novel protein inhibitor, in fighting various cancers. Pleural mesothelioma was one of those cancers in which clear efficacy was demonstrated, raising hopes again for a future second-line therapy option. “It wasn’t the…

The post Tazemetostat Shows Promise for Pleural Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Study statistics show the benefits of the novel transarterial chemoperfusion treatment being used successfully at the Moffitt Cancer Center in Tampa for patients with relapsed pleural mesothelioma. Russell Lamkins — working on the roof of a neighbor’s house — shows them even better. He is living proof. This latest mesothelioma treatment has potential. Lamkins, 73,…

The post Mesothelioma Chemoperfusion Trial Shows Impressive Results appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Patients with pleural mesothelioma cancer may have another treatment option after the U.S. Food and Drug Administration approved the use of pembrolizumab for certain metastatic tumors this week. Pembrolizumab, often known by the brand name Keytruda, is a well-known immunotherapy drug already being used with mixed success for several cancers. This latest FDA approval is…

The post FDA Approves Keytruda for Certain Mesothelioma Patients appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A novel treatment for advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options, according to new research. Transarterial chemoperfusion treatment for malignant pleural mesothelioma (MPM…

A multicenter research team of specialists has uncovered a surprising underutilization of treatments for pleural mesothelioma cancer in women. Clinical Lung Cancer recently published the findings, which showed a significant sex-based disparity in the receipt of care for women when compared with that of men. Women were 15% less likely to receive aggressive mesothelioma surgery…

The post Study Finds Mesothelioma Therapies Underutilized in Women appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Inoperable malignant pleural mesothelioma, is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos.

Consumer concerns and the threat of potentially costly lawsuits are driving cosmetic companies away from the long-standing manufacture of talc-based products. Reuters News Service is reporting that Revlon, Chanel and L’Oreal — three of the biggest names in U.S. cosmetics — have been turning quietly to talc alternatives in the last few years. Talc is…

The post Major Cosmetic Companies Moving Away from Talc in Makeup appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Patients with pleural mesothelioma cancer experienced a significant survival advantage when ramucirumab, a novel immunotherapy drug, was added to chemotherapy in a treatment regimen. Ramucirumab, marketed by Eli Lilly and Company as Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. An ongoing phase…

The post Ramucirumab Shows Promise in Mesothelioma Clinical Trial appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The COVID-19 pandemic closed educational institutions everywhere, but it also opened a door to the acceleration of vitally important asbestos abatement in schools where children would have been in attendance. Business has been booming. “It does look like a lot of schools took advantage of it [the closing of facilities],” Brent Kynoch, managing director of…

The post COVID-19 Closures Accelerate Asbestos Abatement in Schools appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Doctors, scientists and occupational health experts from across the country are openly criticizing the U.S. Environmental Protection Agency’s recent asbestos draft risk evaluation. At a virtual press conference arranged by the Asbestos Disease Awareness Organization last week, speakers labeled the asbestos evaluation inadequate and in need of serious revision. The year-long evaluation was required as…

The post Health Experts Criticize EPA’s Asbestos Draft Risk Evaluation appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

An international, much-anticipated phase III clinical trial that could change standard-of-care treatment for patients with malignant pleural mesothelioma will open soon, pending COVID-19 pandemic restrictions. The randomized trial will be studying the effectiveness of the immunotherapy drug durvalumab (Imfinzi) when used in combination with chemotherapy drugs pemetrexed (Alimta) and cisplatin for mesothelioma. Opening dates may…

The post Durvalumab Phase III Trial Could Change Mesothelioma Care appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Archduke Franz…McDonald?

Surgical oncologist and mesothelioma specialist Dr. Byrne Lee spent close to a decade in Southern California, building a well-respected peritoneal surface malignancy program at City of Hope Comprehensive Cancer Center. He wants to build a bigger and better one now — second to none — almost 400 miles away. The quest is well underway. Lee,…

The post Mesothelioma Specialist Brings HIPEC Expertise to Stanford appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Johnson & Johnson announced Tuesday that it will stop selling its iconic, talc-based baby powder, the target of thousands of lawsuits claiming that its talc was contaminated with asbestos, which led to cancers such as mesothelioma and ovarian cancer. The company said the stoppage is only in the United States and Canada, citing a decline…

The post Johnson & Johnson Ends Talc-Based Baby Powder Sales in US, Canada appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.